Top

Published in:

Open Access 19-08-2023 | Albuminuria | Review

Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy

Authors: Jonathan Goldney, Jack A. Sargeant, Melanie J. Davies

Published in: Diabetologia | Issue 10/2023

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs, incretin mimetics) and dipeptidyl peptidase-4 inhibitors (DPP-4is, incretin enhancers) are glucose-lowering therapies with proven cardiovascular safety, but their effect on microvascular disease is not fully understood. Both therapies increase GLP-1 receptor agonism, which is associated with attenuation of numerous pathological processes that may lead to microvascular benefits, including decreased reactive oxygen species (ROS) production, decreased inflammation and improved vascular function. DPP-4is also increase stromal cell-derived factor-1 (SDF-1), which is associated with neovascularisation and tissue repair. Rodent studies demonstrate several benefits of these agents in the prevention or reversal of nephropathy, retinopathy and neuropathy, but evidence from human populations is less clear. For nephropathy risk in human clinical trials, meta-analyses demonstrate that GLP-1RAs reduce the risk of a composite renal outcome (doubling of serum creatinine, eGFR reduction of 30%, end-stage renal disease or renal death), whereas the benefits of DPP-4is appear to be limited to reductions in the risk of albuminuria. The relationship between GLP-1RAs and retinopathy is less clear. Many large trials and meta-analyses show no effect, but an observed increase in the risk of retinopathy complications with semaglutide therapy (a GLP-1RA) in the SUSTAIN-6 trial warrants caution, particularly in individuals with baseline retinopathy. Similarly, DPP-4is are associated with increased retinopathy risk in both trials and meta-analysis. The association between GLP-1RAs and peripheral neuropathy is unclear due to little trial evidence. For DPP-4is, one trial and several observational studies show a reduced risk of peripheral neuropathy, with others reporting no effect. Evidence in other less-established microvascular outcomes, such as microvascular angina, cerebral small vessel disease, skeletal muscle microvascular disease and autonomic neuropathies (e.g. cardiac autonomic neuropathy, gastroparesis, erectile dysfunction), is sparse. In conclusion, GLP-1RAs are protective against nephropathy, whereas DPP-4is are protective against albuminuria and potentially peripheral neuropathy. Caution is advised with DPP-4is and semaglutide, particularly for patients with background retinopathy, due to increased risk of retinopathy. Well-designed trials powered for microvascular outcomes are needed to clarify associations of incretin therapies and microvascular diseases.

Graphical Abstract

Available only for authorised users

Nauck MA (2020) The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism 103:154031. https://doi.org/10.1016/j.metabol.2019.154031CrossRefPubMed

White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–1335. https://doi.org/10.1056/NEJMoa1305889CrossRefPubMed

Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326. https://doi.org/10.1056/NEJMoa1307684CrossRefPubMed

Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141CrossRefPubMed

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322. https://doi.org/10.1056/NEJMoa1603827CrossRefPubMedPubMedCentral

Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L (2017) The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes Surg 27(10):2724–2732. https://doi.org/10.1007/s11695-017-2866-4CrossRefPubMed

Sista F, Abruzzese V, Clementi M, Carandina S, Cecilia M, Amicucci G (2017) The effect of sleeve gastrectomy on GLP-1 secretion and gastric emptying: a prospective study. Surg Obes Relat Dis 13(1):7–14. https://doi.org/10.1016/j.soard.2016.08.004

Watanabe Y, Kawai K, Ohashi S, Yokota C, Suzuki S, Yamashita K (1994) Structure-activity relationships of glucagon-like peptide-1(7–36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells. J Endocrinol 140(1):45–52. https://doi.org/10.1677/joe.0.1400045CrossRefPubMed

Nauck MA, Heimesaat MM, Behle K et al (2002) Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87(3):1239–1246. https://doi.org/10.1210/jcem.87.3.8355CrossRefPubMed

10.

Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81(1):327–332. https://doi.org/10.1210/jcem.81.1.8550773CrossRefPubMed

11.

Mima A (2016) Incretin-based therapy for prevention of diabetic vascular complications. J Diabetes Res 2016:1379274. https://doi.org/10.1155/2016/1379274CrossRefPubMed

12.

Madonna R, Balistreri CR, Geng Y-J, De Caterina R (2017) Diabetic microangiopathy: pathogenetic insights and novel therapeutic approaches. Vascul Pharmacol 90:1–7. https://doi.org/10.1016/j.vph.2017.01.004CrossRefPubMed

13.

Madonna R, De Caterina R (2011) Cellular and molecular mechanisms of vascular injury in diabetes — part I: pathways of vascular disease in diabetes. Vascul Pharmacol 54(3):68–74. https://doi.org/10.1016/j.vph.2011.03.005CrossRefPubMed

14.

Wang R, Lu L, Guo Y et al (2015) Effect of glucagon-like peptide-1 on high-glucose-induced oxidative stress and cell apoptosis in human endothelial cells and its underlying mechanism. J Cardiovasc Pharmacol 66(2):135–140. https://doi.org/10.1097/FJC.0000000000000255CrossRefPubMed

15.

Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HHW (2010) Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 30(7):1407–1414. https://doi.org/10.1161/ATVBAHA.110.206425CrossRefPubMed

16.

Mima A, Hiraoka-Yamomoto J, Li Q et al (2012) Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes. Diabetes 61(11):2967–2979. https://doi.org/10.2337/db11-1824CrossRefPubMedPubMedCentral

17.

Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi S (2011) Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 60(9):1271–1277. https://doi.org/10.1016/j.metabol.2011.01.010CrossRefPubMed

18.

Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41(10):1286–1292. https://doi.org/10.2337/diab.41.10.1286CrossRefPubMed

19.

Pugliese G (2008) Do advanced glycation end products contribute to the development of long-term diabetic complications? Nutr Metab Cardiovasc Dis 18(7):457–460. https://doi.org/10.1016/j.numecd.2008.06.006

20.

Piarulli F, Sartore G, Lapolla A (2013) Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol 50(2):101–110. https://doi.org/10.1007/s00592-012-0412-3CrossRefPubMed

21.

Strain WD, Paldánius PM (2018) Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol 17(1):57. https://doi.org/10.1186/s12933-018-0703-2CrossRefPubMedPubMedCentral

22.

De Pascale MR, Bruzzese G, Crimi E et al (2016) Severe type 2 diabetes induces reversible modifications of endothelial progenitor cells which are ameliorate by glycemic control. Int J Stem Cells 9(1):137–144. https://doi.org/10.15283/ijsc.2016.9.1.137CrossRefPubMedPubMedCentral

23.

van Ark J, Moser J, Lexis CPH et al (2012) Type 2 diabetes mellitus is associated with an imbalance in circulating endothelial and smooth muscle progenitor cell numbers. Diabetologia 55(9):2501–2512. https://doi.org/10.1007/s00125-012-2590-5CrossRefPubMedPubMedCentral

24.

Packer M (2018) Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. Cardiovasc Diabetol 17(1):9. https://doi.org/10.1186/s12933-017-0648-xCrossRefPubMedPubMedCentral

25.

De Falco E, Porcelli D, Torella AR et al (2004) SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 104(12):3472–3482. https://doi.org/10.1182/blood-2003-12-4423CrossRefPubMed

26.

Fadini GP, Boscaro E, Albiero M et al (2010) The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33(7):1607–1609. https://doi.org/10.2337/dc10-0187CrossRefPubMedPubMedCentral

27.

Aronis KN, Chamberland JP, Mantzoros CS (2013) GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism 62(9):1279–1286. https://doi.org/10.1016/j.metabol.2013.04.010CrossRefPubMedPubMedCentral

28.

Erdogdu O, Nathanson D, Sjöholm A, Nyström T, Zhang Q (2010) Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325(1–2):26–35. https://doi.org/10.1016/j.mce.2010.04.022CrossRefPubMed

29.

Qin X, Zhang Z, Xu H, Wu Y (2011) Notch signaling protects retina from nuclear factor-κB- and poly-ADP-ribose-polymerase-mediated apoptosis under high-glucose stimulation. Acta Biochim Biophys Sin 43(9):703–711. https://doi.org/10.1093/abbs/gmr069CrossRefPubMed

30.

Nauck MA, Quast DR, Wefers J, Pfeiffer AFH (2021) The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Diabetes Obes Metab 23(S3):5–29. https://doi.org/10.1111/dom.14496CrossRefPubMed

31.

Lim D-M, Park K-Y, Hwang W-M, Kim J-Y, Kim B-J (2017) Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response. Exp Ther Med 13(5):2558–2564. https://doi.org/10.3892/etm.2017.4279CrossRefPubMedPubMedCentral

32.

Love KM, Liu J, Regensteiner JG, Reusch JEB, Liu Z (2020) GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. J Diabetes 12(7):488–498. https://doi.org/10.1111/1753-0407.13045CrossRefPubMed

33.

Zhao M, Li CH, Liu YL (2016) Toll-like receptor (TLR)-2/4 expression in retinal ganglion cells in a high-glucose environment and its implications. Genet Mol Res GMR 15(2). https://doi.org/10.4238/gmr.15026998

34.

Panjwani N, Mulvihill EE, Longuet C et al (2013) GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 154(1):127–139. https://doi.org/10.1210/en.2012-1937CrossRefPubMed

35.

Daousi C, Pinkney JH, Cleator J, Wilding JP, Ranganath LR (2013) Acute peripheral administration of synthetic human GLP-1 (7–36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state? Regul Pept 183:54–61. https://doi.org/10.1016/j.regpep.2013.03.004CrossRefPubMed

36.

Arakawa M, Mita T, Azuma K et al (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59(4):1030–1037. https://doi.org/10.2337/db09-1694CrossRefPubMedPubMedCentral

37.

Verkman AS (2011) Aquaporins at a glance. J Cell Sci 124(13):2107–2112. https://doi.org/10.1242/jcs.079467CrossRefPubMed

38.

Amano H, Ito Y, Suzuki T et al (2009) Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Sci 100(12):2318–2324. https://doi.org/10.1111/j.1349-7006.2009.01322.xCrossRefPubMed

39.

Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60(5):1306–1311PubMed

40.

Spektor G, Fuster V (2005) Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk–where are we now? Nat Clin Pract Cardiovasc Med 2(6):290–300. https://doi.org/10.1038/ncpcardio0214CrossRefPubMed

41.

Lechner J, O’Leary OE, Stitt AW (2017) The pathology associated with diabetic retinopathy. Vision Res 139:7–14. https://doi.org/10.1016/j.visres.2017.04.003CrossRefPubMed

42.

Carmines PK (2010) The renal vascular response to diabetes. Curr Opin Nephrol Hypertens 19(1):85–90. https://doi.org/10.1097/MNH.0b013e32833240fcCrossRefPubMedPubMedCentral

43.

Tsapas A, Karagiannis T, Kakotrichi P et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 23(9):2116–2124. https://doi.org/10.1111/dom.14451CrossRefPubMed

44.

Sun F, Wu S, Wang J et al (2015) Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther 37(1):225-241.e8. https://doi.org/10.1016/j.clinthera.2014.11.008CrossRefPubMed

45.

Jolivalt CG, Fineman M, Deacon CF, Carr RD, Calcutt NA (2011) GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes Metab 13(11):990–1000. https://doi.org/10.1111/j.1463-1326.2011.01431.xCrossRefPubMedPubMedCentral

46.

Fadini GP, Avogaro A (2018) How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors. Cardiovasc Diabetol 17(1):22. https://doi.org/10.1186/s12933-018-0668-1CrossRefPubMedPubMedCentral

47.

Greco C, Santi D, Brigante G, Pacchioni C, Simoni M (2022) Effect of the glucagon-like peptide-1 receptor agonists on autonomic function in subjects with diabetes: a systematic review and meta-analysis. Diabetes Metab J 46(6):901–911. https://doi.org/10.4093/dmj.2021.0314CrossRefPubMedPubMedCentral

48.

Kim BJ, Lee JK, Schuchman EH, Jin HK, Bae J (2013) Synergistic vasculogenic effects of AMD3100 and stromal-cell-derived factor-1α in vasa nervorum of the sciatic nerve of mice with diabetic peripheral neuropathy. Cell Tissue Res 354(2):395–407. https://doi.org/10.1007/s00441-013-1689-4CrossRefPubMed

49.

Butler JM, Guthrie SM, Koc M et al (2005) SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest 115(1):86–93. https://doi.org/10.1172/JCI22869CrossRefPubMedPubMedCentral

50.

Broxmeyer HE, Hoggatt J, O’Leary HA et al (2012) Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med 18(12):1786–1796. https://doi.org/10.1038/nm.2991CrossRefPubMedPubMedCentral

51.

Bae EJ (2016) DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control. Arch Pharm Res 39(8):1114–1128. https://doi.org/10.1007/s12272-016-0813-xCrossRefPubMed

52.

Chalmoukou K, Polyzos D, Manta E et al (2022) Renal outcomes associated with glucose-lowering agents: systematic review and meta-analysis of randomized outcome trials. Eur J Intern Med 97:78–85. https://doi.org/10.1016/j.ejim.2021.12.018CrossRefPubMed

53.

Yoshiji S, Minamino H, Tanaka D, Yamane S, Harada N, Inagaki N (2022) Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: a meta-analysis and meta-regression analysis. Diabetes Obes Metab 24(6):1029–1037. https://doi.org/10.1111/dom.14666CrossRefPubMed

54.

Rossing P, Baeres FMM, Bakris G et al (2023) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant gfad009. https://doi.org/10.1093/ndt/gfad009

55.

Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321(1):69–79. https://doi.org/10.1001/jama.2018.18269CrossRefPubMed

56.

Mosenzon O, Leibowitz G, Bhatt DL et al (2017) Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 40(1):69–76. https://doi.org/10.2337/dc16-0621CrossRefPubMed

57.

Xie Y, Bowe B, Gibson AK et al (2020) Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care 43(11):2859–2869. https://doi.org/10.2337/dc20-1890CrossRefPubMed

58.

Gilbert MP, Pratley RE (2020) GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol 11:178. https://doi.org/10.3389/fendo.2020.00178CrossRef

59.

Saw M, Wong VW, Ho I-V, Liew G (2019) New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy. Eye Lond Engl 33(12):1842–1851. https://doi.org/10.1038/s41433-019-0494-zCrossRef

60.

Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC (2021) HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care 44(1):290–296. https://doi.org/10.2337/dc20-1815CrossRefPubMed

61.

Andreadis P, Karagiannis T, Malandris K et al (2018) Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 20(9):2255–2263. https://doi.org/10.1111/dom.13361CrossRefPubMed

62.

Wei J, Yang B, Wang R et al (2022) Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis. Front Endocrinol 13:1007980. https://doi.org/10.3389/fendo.2022.1007980CrossRef

63.

Yoshida Y, Joshi P, Barri S et al (2022) Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - a systematic review and meta-analysis. J Diabetes Complications 36(8):108255. https://doi.org/10.1016/j.jdiacomp.2022.108255CrossRefPubMed

64.

Goldenberg RM (2022) Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - a systematic review and meta-analysis. J Diabetes Complications 36(9):108285. https://doi.org/10.1016/j.jdiacomp.2022.108285CrossRefPubMed

65.

Qian W, Liu F, Yang Q (2021) Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: a meta-analysis. J Clin Pharm Ther 46(6):1650–1658. https://doi.org/10.1111/jcpt.13502CrossRefPubMed

66.

Wang F, Mao Y, Wang H, Liu Y, Huang P (2022) Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Clin Drug Investig 42(1):17–28. https://doi.org/10.1007/s40261-021-01110-wCrossRefPubMed

67.

Vilsbøll T, Bain SC, Leiter LA et al (2018) Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20(4):889–897. https://doi.org/10.1111/dom.13172CrossRefPubMedPubMedCentral

68.

The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 116(7):874–886. https://doi.org/10.1001/archopht.116.7.874CrossRef

69.

Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S et al (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986. https://doi.org/10.1056/NEJM199309303291401CrossRef

70.

ClinicalTrials.gov (2023) A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS). https://clinicaltrials.gov/ct2/show/NCT03811561. Accessed 23 May 2023

71.

Kolaczynski WM, Hankins M, Ong SH, Richter H, Clemens A, Toussi M (2016) Microvascular outcomes in patients with type 2 diabetes treated with vildagliptin vs. sulfonylurea: a retrospective study using german electronic medical records. Diabetes Ther Res Treat Educ Diabetes Relat Disord 7(3):483–496. https://doi.org/10.1007/s13300-016-0177-8CrossRef

72.

Chung Y-R, Park SW, Kim JW, Kim JH, Lee K (2016) Protective effects of dipeptidyl peptidase-4 inhibitors on progression of diabetic retinopathy in patients with type 2 diabetes. Retina Phila Pa 36(12):2357–2363. https://doi.org/10.1097/IAE.0000000000001098CrossRef

73.

Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373(3):232–242. https://doi.org/10.1056/NEJMoa1501352CrossRefPubMed

74.

Tang H, Li G, Zhao Y et al (2018) Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis. Diabetes Obes Metab 20(5):1262–1279. https://doi.org/10.1111/dom.13232CrossRefPubMed

75.

Sango K, Takaku S, Tsukamoto M, Niimi N, Yako H (2022) Glucagon-like peptide-1 receptor agonists as potential myelination-inducible and anti-demyelinating remedies. Front Cell Dev Biol 10:950623. https://doi.org/10.3389/fcell.2022.950623CrossRefPubMedPubMedCentral

76.

Deng Y, Polley EC, Wallach JD et al (2022) Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. BMJ 379:e070717. https://doi.org/10.1136/bmj-2022-070717CrossRefPubMedPubMedCentral

77.

GRADE Study Research Group, Nathan DM, Lachin JM et al (2022) Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes. N Engl J Med 387(12):1075–1088. https://doi.org/10.1056/NEJMoa2200436CrossRef

78.

El Mouhayyar C, Riachy R, Khalil AB, Eid A, Azar S (2020) SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors in diabetes and microvascular complications: a review. Int J Endocrinol 2020:1762164. https://doi.org/10.1155/2020/1762164CrossRefPubMedPubMedCentral

79.

Gabriel R, Boukichou-Abdelkader N, Gilis-Januszewska A et al (2023) Reduction in the risk of peripheral neuropathy and lower decrease in kidney function with metformin, linagliptin or their fixed-dose combination compared to placebo in prediabetes: A randomized controlled trial. J Clin Med 12(5):2035. https://doi.org/10.3390/jcm12052035CrossRefPubMedPubMedCentral

80.

Spallone V (2019) Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet. Diabetes Metab J 43(1):3–30. https://doi.org/10.4093/dmj.2018.0259CrossRefPubMed

81.

Pauza AG, Thakkar P, Tasic T et al (2022) GLP1R attenuates sympathetic response to high glucose via carotid body inhibition. Circ Res 130(5):694–707. https://doi.org/10.1161/CIRCRESAHA.121.319874CrossRefPubMedPubMedCentral

82.

Beti C, Stratmann B, Bokman G et al (2019) Exenatide delays gastric emptying in patients with type 2 diabetes mellitus but not in those with gastroparetic conditions. Horm Metab Res 51(4):267–273. https://doi.org/10.1055/a-0818-6374CrossRefPubMed

83.

Bharucha AE, Batey-Schaefer B, Cleary PA et al (2015) Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus. Gastroenterology 149(2):330–339. https://doi.org/10.1053/j.gastro.2015.05.007CrossRefPubMed

84.

MacDonald SM, Burnett AL (2021) Physiology of erection and pathophysiology of erectile dysfunction. Urol Clin North Am 48(4):513–525. https://doi.org/10.1016/j.ucl.2021.06.009CrossRefPubMed

85.

Bajaj HS, Gerstein HC, Rao-Melacini P et al (2021) Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes Endocrinol 9(8):484–490. https://doi.org/10.1016/S2213-8587(21)00115-7CrossRefPubMed

86.

Evans LE, Taylor JL, Smith CJ, Pritchard HAT, Greenstein AS, Allan SM (2021) Cardiovascular comorbidities, inflammation, and cerebral small vessel disease. Cardiovasc Res 117(13):2575–2588. https://doi.org/10.1093/cvr/cvab284CrossRefPubMed

87.

Abushamat LA, McClatchey PM, Scalzo RL et al (2020) Mechanistic causes of reduced cardiorespiratory fitness in type 2 diabetes. J Endocr Soc 4(7):bvaa063. https://doi.org/10.1210/jendso/bvaa063CrossRefPubMedPubMedCentral

88.

Yates T, Henson J, Sargeant J et al (2021) Exercise, pharmaceutical therapies and type 2 diabetes: looking beyond glycemic control to whole body health and function. Transl Med Exerc Prescr 1(1):33–42. https://doi.org/10.53941/tmep.v1i1.33CrossRef

89.

Hammes H-P, Lin J, Renner O et al (2002) Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51(10):3107–3112. https://doi.org/10.2337/diabetes.51.10.3107CrossRefPubMed

90.

Nyström T, Gutniak MK, Zhang Q et al (2004) Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287(6):E1209–E1215. https://doi.org/10.1152/ajpendo.00237.2004CrossRefPubMed

91.

Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116(11):3015–3025. https://doi.org/10.1172/JCI28898CrossRefPubMedPubMedCentral

92.

Favale NO, Casali CI, Lepera LG, Pescio LG, Fernández-Tome MC (2009) Hypertonic induction of COX2 expression requires TonEBP/NFAT5 in renal epithelial cells. Biochem Biophys Res Commun 381(3):301–305. https://doi.org/10.1016/j.bbrc.2008.12.189CrossRefPubMed

93.

Issar T, Kwai NCG, Poynten AM, Arnold R, Milner K-L, Krishnan AV (2021) Effect of exenatide on peripheral nerve excitability in type 2 diabetes. Clin Neurophysiol 132(10):2532–2539. https://doi.org/10.1016/j.clinph.2021.05.033CrossRefPubMed

94.

Ponirakis G, Abdul-Ghani MA, Jayyousi A et al (2020) Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study. BMJ Open Diabetes Res Care 8(1):e001420. https://doi.org/10.1136/bmjdrc-2020-001420CrossRefPubMedPubMedCentral

95.

Jaiswal M, Martin CL, Brown MB et al (2015) Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. J Diabetes Complications 29(8):1287–1294. https://doi.org/10.1016/j.jdiacomp.2015.07.013CrossRefPubMedPubMedCentral

96.

Brock C, Hansen CS, Karmisholt J et al (2019) Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. Br J Clin Pharmacol 85(11):2512–2523. https://doi.org/10.1111/bcp.14063CrossRefPubMedPubMedCentral

97.

Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L (2009) A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. Pharmacotherapy 29(11):1280–1288. https://doi.org/10.1592/phco.29.11.1280CrossRefPubMed

98.

da Silva GM, Heise CO, Hirata MT et al (2015) Comparative effects of a dipeptidyl peptidase-4 inhibitor and of NPH insulin on peripheral nerve conduction of patients with type 2 diabetes. Diabetol Metab Syndr 7(Suppl 1):A59. https://doi.org/10.1186/1758-5996-7-S1-A59CrossRefPubMedCentral

99.

Engel SS, Suryawanshi S, Stevens SR et al (2017) Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes Obes Metab 19(11):1587–1593. https://doi.org/10.1111/dom.12983CrossRefPubMed

Title: Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
Authors: Jonathan Goldney
Jack A. Sargeant
Melanie J. Davies
Publication date: 19-08-2023
Publisher: Springer Berlin Heidelberg
Keywords: Albuminuria
Sitagliptin
Exenatide
Liraglutide
Incretin Mimetics
Incretin Mimetics
Semaglutide
Type 2 Diabetes
Published in: Diabetologia / Issue 10/2023
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-023-05988-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 10/2023

Genetic associations vary across the spectrum of fasting serum insulin: results from the European IDEFICS/I.Family children’s cohort

Up Front

Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy

Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production

Reversal of dual epigenetic repression of non-canonical Wnt-5a normalises diabetic corneal epithelial wound healing and stem cells

Incretin hormones and type 2 diabetes

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage